Amgen (BUE:AMGN) Construction In Progress: ARS0 Mil (As of Mar. 2026)


BUE:AMGN Amgen Inc BUE:AMGN
83 GF Score
Price ARS19,580.00
GF Value ARS18,504.06
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is Amgen Construction In Progress?

Amgen BUE:AMGN +3.65% 83 Construction In Progress is ARS0 Mil as of Mar. 2026. GuruFocus rates BUE:AMGN with a GF Score™ of 83/100 and a GF Value™ of ARS18,504.06 (Fairly Valued). The stock has 9 warning signs investors should review.

Amgen's quarterly construction in progress increased from Sep. 2025 (ARS0 Mil) to Dec. 2025 (ARS4,920,548 Mil) but then declined from Dec. 2025 (ARS4,920,548 Mil) to Mar. 2026 (ARS0 Mil).

Amgen's annual construction in progress increased from Dec. 2023 (ARS559,550 Mil) to Dec. 2024 (ARS2,073,530 Mil) and increased from Dec. 2024 (ARS2,073,530 Mil) to Dec. 2025 (ARS4,920,548 Mil).

Amgen Construction In Progress Historical Data

* Premium members only.

The historical data trend for Amgen's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amgen Construction In Progress Chart

Amgen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 99,677.13 203,359.44 559,550.00 2,073,530.02 4,920,547.67

Amgen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 4,920,547.67 0.00
BUE:AMGN
83GF Score
Amgen Inc BUE:AMGN
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amgen Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of ARS0 Mil mean?
Amgen (BUE:AMGN) has a Construction In Progress of ARS0 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Amgen and its competitors.
Is Amgen's Construction In Progress too high?
Amgen's current Construction In Progress is ARS0 Mil. Overall, Amgen has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Amgen's Construction In Progress compare to GILD and PFE?
Amgen's Construction In Progress of ARS0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Amgen and its competitors. Amgen's current Construction In Progress is ARS0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Based on GuruFocus' analysis, Amgen (BUE:AMGN) is currently considered Fairly Valued. The stock's GF Value™ is ARS18,504.06, compared to a current price of ARS19,580.00 — trading 5.8% above its estimated fair value. The current Construction In Progress is ARS0 Mil. Amgen's overall GF Score™ is 83/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Amgen (BUE:AMGN), the current Construction In Progress is ARS0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amgen (BUE:AMGN) Overvalued in 2026?

Based on GuruFocus' analysis, Amgen stock appears to be overvalued. The current stock price of ARS19,580.00 is trading 5.8% above its estimated GF Value™ of ARS18,504.06. GuruFocus considers Amgen to be Fairly Valued.

Key valuation signals for BUE:AMGN:

  • Construction In Progress: ARS0 Mil
  • GF Value™: ARS18,504.06 vs. price of ARS19,580.00 (5.8% above fair value)
  • GF Score™: 83/100 with 9 warning signs

No single metric tells the full story. See the BUE:AMGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amgen Business Description

Address One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
83GF Score

Get the complete analysis for BUE:AMGN

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS19,580.00
Price
ARS18,504.06
GF Value